Prostamax vs Melanotan 1
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ProstamaxSkin & CosmeticSexual Health & Libido
Melanotan 1- Summary
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.5–1 mg
- Frequency
- Daily for 10–30 days
- Daily until desired color achieved, then maintenance
- Key Benefits
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Induces skin pigmentation/tanning without UV exposure
- Provides photoprotection in photosensitivity conditions (EPP)
- FDA-approved for erythropoietic protoporphyria (SCENESSE)
- Approved in EU for EPP treatment
- Anti-inflammatory via MC1R
- Mild libido enhancement
- Potential skin cancer prevention through melanin protection
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Nausea (especially at higher doses)
- Facial flushing
- Fatigue
- Injection site reactions
- +3 more
- Stacks With
- —
- —